Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Veterinary Vaccines and One Health
share announcement

Veterinary Vaccines and One Health

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".

Deadline for manuscript submissions: closed (1 November 2022) | Viewed by 11109

Special Issue Editors

Prof. Dr. Richard A. Bowen

E-Mail Website
Guest Editor
Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80521, USA
Interests: viral diseases; zoonotic pathogens; MERS-CoV
Special Issues, Collections and Topics in MDPI journals
Dr. Danielle Adney

E-Mail Website
Guest Editor
Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA
Interests: pathogenesis; animal modeling; zoonotic spillover; transmission

Special Issue Information

Dear Colleagues,

We are delighted to announce the launch of a Special Issue focusing on “Veterinary Vaccines and One Health.” As zoonotic spillover events continue to increase in frequency, multiple strategies to control outbreaks are necessary to protect human health. Such a strategy is multi-faceted and relies on vaccine availability for companion animals, livestock, and wildlife. However, these require unqiue consideration for vaccine protocols to accommodate challenges such as distribution, repeat vaccination, and surviellence. 

In this Special Issue, original research articles, communications, reviews, and case studies are welcome. Research areas may include (but not limited to) the following: wildlife vaccine strategies, transmissible vaccines, companion animal preventative health, pre-clinical and clinical trials, and methods for assessing vaccine efficacy.

Prof. Dr. Richard A. Bowen
Dr. Danielle Adney
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • veterinary vaccines
  • wildlife vaccine strategies
  • transmissible vaccines
  • companion animal preventative health

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 14629 KiB  
Article
A Novel Vaccine Strategy to Prevent Cytauxzoonosis in Domestic Cats
by Pabasara Weerarathne, Rebekah Maker, Chaoqun Huang, Brianne Taylor, Shannon R. Cowan, Julia Hyatt, Miruthula Tamil Selvan, Shoroq Shatnawi, Jennifer E. Thomas, James H. Meinkoth, Ruth Scimeca, Adam Birkenheuer, Lin Liu, Mason V. Reichard and Craig A. Miller
Vaccines 2023, 11(3), 573; https://doi.org/10.3390/vaccines11030573 - 02 Mar 2023
Viewed by 2743
Abstract
Cytauxzoonosis is caused by Cytauxzoon felis (C. felis), a tick-borne parasite that causes severe disease in domestic cats in the United States. Currently, there is no vaccine to prevent this fatal disease, as traditional vaccine development strategies have been limited by [...] Read more.
Cytauxzoonosis is caused by Cytauxzoon felis (C. felis), a tick-borne parasite that causes severe disease in domestic cats in the United States. Currently, there is no vaccine to prevent this fatal disease, as traditional vaccine development strategies have been limited by the inability to culture this parasite in vitro. Here, we used a replication-defective human adenoviral vector (AdHu5) to deliver C. felis-specific immunogenic antigens and induce a cell-mediated and humoral immune response in cats. Cats (n = 6 per group) received either the vaccine or placebo in two doses, 4 weeks apart, followed by experimental challenge with C. felis at 5 weeks post-second dose. While the vaccine induced significant cell-mediated and humoral immune responses in immunized cats, it did not ultimately prevent infection with C. felis. However, immunization significantly delayed the onset of clinical signs and reduced febrility during C. felis infection. This AdHu5 vaccine platform shows promising results as a vaccination strategy against cytauxzoonosis. Full article
(This article belongs to the Special Issue Veterinary Vaccines and One Health)
►▼ Show Figures

Figure 1

12 pages, 1273 KiB  
Article
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
by Naif Khalaf Alharbi, Fahad Aljamaan, Haya A. Aljami, Mohammed W. Alenazi, Hind Albalawi, Abdulrahman Almasoud, Fatima J. Alharthi, Esam I. Azhar, Tlili Barhoumi, Mohammad Bosaeed, Sarah C. Gilbert and Anwar M. Hashem
Vaccines 2022, 10(8), 1330; https://doi.org/10.3390/vaccines10081330 - 17 Aug 2022
Cited by 4 | Viewed by 2290
Abstract
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic pathogen that can transmit from dromedary camels to humans, causing severe pneumonia, with a 35% mortality rate. Vaccine candidates have been developed and tested in mice, camels, and humans. Previously, we developed a [...] Read more.
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic pathogen that can transmit from dromedary camels to humans, causing severe pneumonia, with a 35% mortality rate. Vaccine candidates have been developed and tested in mice, camels, and humans. Previously, we developed a vaccine based on the modified vaccinia virus Ankara (MVA) viral vector, encoding a full-length spike protein of MERS-CoV, MVA-MERS. Here, we report the immunogenicity of high-dose MVA-MERS in prime–boost vaccinations in mice and camels. Methods: Three groups of mice were immunised with MVA wild-type (MVA-wt) and MVA-MERS (MVA-wt/MVA-MERS), MVA-MERS/MVA-wt, or MVA-MERS/MVA-MERS. Camels were immunised with two doses of PBS, MVA-wt, or MVA-MERS. Antibody (Ab) responses were evaluated using ELISA and MERS pseudovirus neutralisation assays. Results: Two high doses of MVA-MERS induced strong Ab responses in both mice and camels, including neutralising antibodies. Anti-MVA Ab responses did not affect the immune responses to the vaccine antigen (MERS-CoV spike). Conclusions: MVA-MERS vaccine, administered in a homologous prime–boost regimen, induced high levels of neutralising anti-MERS-CoV antibodies in mice and camels. This could be considered for further development and evaluation as a dromedary vaccine to reduce MERS-CoV transmission to humans. Full article
(This article belongs to the Special Issue Veterinary Vaccines and One Health)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 373 KiB  
Review
Vaccine Preventable Zoonotic Diseases: Challenges and Opportunities for Public Health Progress
by Ann Carpenter, Michelle A. Waltenburg, Aron Hall, James Kile, Marie Killerby, Barbara Knust, Maria Negron, Megin Nichols, Ryan M. Wallace, Casey Barton Behravesh, Jennifer H. McQuiston and the Vaccine Preventable Zoonotic Disease Working Group
Vaccines 2022, 10(7), 993; https://doi.org/10.3390/vaccines10070993 - 22 Jun 2022
Cited by 10 | Viewed by 5379
Abstract
Zoonotic diseases represent a heavy global burden, causing important economic losses, impacting animal health and production, and costing millions of human lives. The vaccination of animals and humans to prevent inter-species zoonotic disease transmission is an important intervention. However, efforts to develop and [...] Read more.
Zoonotic diseases represent a heavy global burden, causing important economic losses, impacting animal health and production, and costing millions of human lives. The vaccination of animals and humans to prevent inter-species zoonotic disease transmission is an important intervention. However, efforts to develop and implement vaccine interventions to reduce zoonotic disease impacts are often limited to the veterinary and agricultural sectors and do not reflect the shared burden of disease. Multisectoral collaboration, including co-development opportunities for human and animal vaccines, expanding vaccine use to include animal reservoirs such as wildlife, and strategically using vaccines to interrupt complex transmission cycles is needed. Addressing zoonoses requires a multi-faceted One Health approach, wherein vaccinating people and animals plays a critical role. Full article
(This article belongs to the Special Issue Veterinary Vaccines and One Health)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop